|Bid||25.00 x 14500|
|Ask||25.20 x 13900|
|Day's range||25.00 - 25.20|
|52-week range||20.00 - 34.60|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||8.68|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it, in partnership with Illinois Governor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology Innovation Organization (iBIO) Institute’s COVID-19 Response Fund.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Down and Out Kidney, a campaign to highlight the damaging effects associated with the accumulation of uric acid and gout in people with chronic kidney disease (CKD).
Horizon Therapeutics (Nasdaq: HZNP) and Willis Towers Watson (Nasdaq: WLTW) are partnering with Willis Tower to light the antennas of the Willis Tower on Feb. 29 in recognition of Rare Disease Day and to raise awareness of the crucial need to identify new medicines for the 30 million people living with rare diseases in the United States. The antennas will be illuminated in the colors of the rising sun (Horizon’s corporate colors) elevating Horizon’s commitment to partnering with the community to raise awareness and bring forward new medicines for rare diseases.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced a $1 million commitment over five years to establish the RAREis scholarship, a program that will be made available by the EveryLife Foundation for Rare Diseases. The RAREis scholarship will support the pursuit of life enrichment activities for adults living with rare diseases for a variety of educational pursuits, including educational courses, travel stipends for rare disease conferences and obtaining two-and four-year degrees.
Horizon Therapeutics plc (Nasdaq: NZNP) today announced that it has been recognized as one of the 2020 Best Workplaces in Ireland, ranking 13th in the small company category. This is the first year that Horizon has been named to the Ireland list.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its fourth-quarter and full-year 2019 financial results and provided its full-year 2020 net sales and adjusted EBITDA guidance.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March:
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis. This new dosage form provides another option for people living with cystinosis, in addition to the currently available PROCYSBI capsules.
Horizon Therapeutics plc (Nasdaq: HZNP) and Uplifting Athletes today announced a new partnership for the 2020 Reps for Rare Disease campaign, which offers an opportunity for NFL Draft prospects to give back and support the rare disease community. Participants who team up with Uplifting Athletes will dedicate their performance in one event – bench press, vertical jump or broad jump – at the NFL Scouting Combine or their school’s official pro day, to raising funds for rare disease research and awareness initiatives.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
On a per-share basis, the Dublin-based company said it had a loss of 19 cents. Earnings, adjusted for non-recurring costs, came to 30 cents per share. The results surpassed Wall Street expectations. The ...
A tiny, little-known government agency is ramping up regulation of Canada's pharmaceutical industry, seeking to rein in prices for patented drugs that are among the highest in the world, according to industry sources and a Reuters analysis of government data. The federal Patented Medicine Prices Review Board (PMPRB) is targeting an increasing number of expensive drugs, including a rare-disease medication made by Horizon Pharma that can cost C$325,000 ($253,409) a year, documents reviewed by Reuters shows. The agency can challenge the list price of any patented drug in Canada and order companies to repay some revenue.